Sandwich ELISA, Biotin-labelled antibody
At ambient temperature. Upon receipt, store the product at the temperature recommended below.
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Limit of Detection
- Highly specific and sensitive assay for quantitative detection of IGFBP-2 in mouse and rat serum
- Recombinant mouse IGFBP-2 as standard
- Uses antibodies against complete mouse and rat IGFBP-2
- No sample extraction is required
- Detection limit: 0.01 ng/ml
Growth hormone and factor-related products, Oncology, Animal studies
Insulin-like growth factors (IGFs) regulate the proliferation, differentation, apoptosis, cell adhesion and metabolism in various tissues and cell types. The IGF-1, which is produced mainly in liver under the influence of Growth Hormone (GH), regulates as hormone the linear growth of the bones and the process of sexual maturity, while IGF-II is mainly a growth factor of foetal tissue. The biological actions of IGF over the IGF-Type-1 receptor
are modulated variably through the IGF binding proteins (IGFBP-1 to-6). IGFBP-2 is, after IGFBP-3, the second most frequent IGFBP in the human blood. IGFs, especially tumor typical pro-IGF-forms and hormones
regulate the expression of IGFBP-2, GH effect is thereby inhibiting. At cellular level IGFBP-2 seems to stimulate
the proliferation and dissemination of solid tumors via an IGF-independent mechanism.
IGFBP-2 is an unglycosylated polypetide of 31.3 kDa, which forms binary IGF-complexes and shows no circadian rhythm in the circulation. The serum concentration of IGFBP-2 increases in fasting, after major surgery and after trauma, but the increasing of the concentration is most intensive in malignant diseases. The correlation of the IGFBP-2 level to the degree of progression is a striking feature in various tumor types as is the normalization of the IGFBP-serum levels after remission (5-10). During the GH-therapy, e.g. in short stature and in GH-abuse (doping) the IGFBP-2 level decreases. In Trisomy 18 IGFBP-2 in maternal serum is decreased and IGFBP-1 is increased; therefore the ratio IGFBP-2 /IGFBP-1 is a marker for this chromosome abnormality.
Transgenic organisms are a good opportunity to investigate the function of genes or proteins. The mouse or rat model is a well-suited system for investigation of the relevance of IGFBP-2 in physiological and pathological processes. Over expression of the IGFBP-2 gene in mice results in a weight reduction of 30% in spleen and moderately reduced weight in other organs. Effects of IGFBP-2 on the organism can be compensated through the modified expression of other IGF-Binding proteins. Especially in tumor biology the mouse and rat systems enable investigation of the systemic relevance of IGFBP-2. IGFBP-2 influences tumor cells as it induces catalase activity in adrenocortical cells. Furthermore IGFBP-2 interacts with tumor cells via its RGD-amino acid sequence and seems to stimulate cell invasion of glioma cells.